Arcadia Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Product | $1,302 | $1,537 | $3,957 | $3,829 |
| Total revenues | 1,302 | 1,537 | 3,957 | 3,829 |
| Operating expenses (income): | ||||
| Cost of revenues | 884 | 1,032 | 2,389 | 2,136 |
| Research and development | — | 24 | 9 | 40 |
| Gain on sale of intangible assets | — | — | (750) | (4,000) |
| Impairment of property and equipment | — | — | — | 36 |
| Change in fair value of contingent consideration | — | — | (2,000) | — |
| Selling, general and administrative | 1,570 | 2,241 | 5,434 | 6,986 |
| Total operating expenses | 2,454 | 3,297 | 5,082 | 5,198 |
| Loss from operations | (1,152) | (1,760) | (1,125) | (1,369) |
| Interest income | 7 | 233 | 222 | 428 |
| Credit loss | (257) | — | (4,745) | — |
| Other income | 1,698 | 15 | 2,770 | 168 |
| Change in fair value of common stock warrant and option liabilities | 560 | 330 | 1,875 | 493 |
| Net income (loss) from continuing operations | 856 | (1,182) | (1,003) | (280) |
| Net loss from discontinued operations | — | (430) | — | (2,694) |
| Net income (loss) attributable to common stockholders | $856 | $(1,612) | $(1,003) | $(2,974) |
| Net income (loss) per share attributable to common stockholders: | ||||
| Basic from continuing operations | $0.63 | $(0.87) | $(0.73) | $(0.21) |
| Basic from discontinued operations | $— | $(0.32) | $— | $(1.98) |
| Net income (loss) per basic share attributable to common stockholders | $0.63 | $(1.18) | $(0.73) | $(2.18) |
| Diluted from continuing operations | $0.62 | $(0.87) | $(0.73) | $(0.21) |
| Diluted from discontinued operations | $— | $(0.32) | $— | $(1.98) |
| Net income (loss) per diluted share attributable to common stockholders | $0.62 | $(1.18) | $(0.73) | $(2.18) |
| Weighted-average number of shares used in per share calculations: | ||||
| Basic | 1,367,192 | 1,363,753 | 1,366,768 | 1,362,754 |
| Diluted | 1,371,879 | 1,363,753 | 1,366,768 | 1,362,754 |
| Other comprehensive income, net of tax | ||||
| Unrealized gains on available-for-sale securities | $— | $36 | $— | $117 |
| Reclassification adjustment for gains on available-for-sale securities included in net income (loss) | — | — | — | (111) |
| Change in unrealized gains on available-for-sale securities | $— | $36 | $— | $6 |
| Comprehensive income (loss) | $856 | $(1,576) | $(1,003) | $(2,968) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.